The 4 most recent market catalysts affecting $ALMR, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.
Nov 3, 2026
Corporate Catalyst
Bullish
Impact 65
Alamar Biosciences Announces Strategic Scientific Collaboration with GSK
Alamar Biosciences has entered into a strategic scientific collaboration with GSK, a major pharmaceutical company, to utilize Alamar's NULISA platform for investigating protein sig…
Aug 11, 2026
Corporate Catalyst
Bullish
Impact 55
Stifel Maintains Buy on Alamar Biosciences, Raises Price Target to $32
Stifel analyst Daniel Arias maintained a 'Buy' rating on Alamar Biosciences and raised the price target from $28 to $32. This action indicates a continued bullish outlook from the …
Aug 11, 2026
Corporate Catalyst
Bullish
Impact 85
Alamar Biosciences Stock Soars, CEO Says Company Is Well-Positioned to Sustain Upcoming Momentum
Alamar Biosciences (ALMR) shares soared following the announcement of an expanded partnership with the Alzheimer’s Disease Data Initiative and Gates Ventures. This collaboration wi…
Aug 11, 2026
Corporate Catalyst
Bullish
Impact 65
JP Morgan Maintains Overweight on Alamar Biosciences, Raises Price Target to $35
This filing discloses that JP Morgan has reaffirmed its 'Overweight' rating on Alamar Biosciences (ALMR) and raised its price target from $32 to $35. This analyst action is signifi…
Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.